Synthesis of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The article presents a method for the preparation of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside from (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-1,2-O-isopropylidene-α-L-talofuranoside by successive treatment of the latter with a 20% solution of hydrochloric acid in aqueous methanol, followed by treatment with benzoyl chloride in dry pyridine. A promising use of methyl (1S,2S,3R,4R,5S)-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside for the synthesis of new modified nucleosides after its acetylation has also been shown.

Sobre autores

M. Khalikova

V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan

Email: diavoly@mail.ru
Tajiquistão, ul. Ayni, 299/2, Dushanbe, 734063

U. Roziqov

V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan

Email: diavoly@mail.ru
Tajiquistão, ul. Ayni, 299/2, Dushanbe, 734063

A. Skrylkova

St. Petersburg State Institute of Technology (Technical University)

Email: diavoly@mail.ru
Rússia, Moskovskii prosp., 26, St. Petersburg, 190013

D. Egorov

St. Petersburg State Institute of Technology (Technical University)

Autor responsável pela correspondência
Email: diavoly@mail.ru
ORCID ID: 0000-0003-3744-9306
Rússia, Moskovskii prosp., 26, St. Petersburg, 190013

S. Safarov

V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan

Email: diavoly@mail.ru
ORCID ID: 0000-0002-7193-6135
Tajiquistão, ul. Ayni, 299/2, Dushanbe, 734063

Bibliografia

  1. Fischer E., Piloty O. Ber. Dtsch. Chem. Ges. 1891, 24, 4214–4225. doi: 10.1002/cber.189102402322
  2. Eugenio F., Lourdes R. J. Biol. Chem. 2019, 294, 2249–2255. doi: 10.1074/jbc.CL119.007397.
  3. Jeanloz R.W., Fletcher H. G. Adv. Carbohydr. Chem. 1951, 6, 135–174. doi: 10.1016/S0096–5332(08)60066–1.
  4. Mao-Chin L., Mei-Zhen L., Diane E. M., Alan C. S. Nucleosid. Nucleotid. Nucleic. Acids. 2005, 24, 45–62. doi: 10.1081/NCN-46784.
  5. Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Bioorg. Chem. 2016, 65, 9–16. doi: 10.1016/j.bioorg.2015.12.006.
  6. Chhikara B.S., Parang K. Expert Opin. Drug Deliv. 2010, 7, 1399–1414. doi: 10.1517/17425247.2010.527330.
  7. Li Y., Li P., Li Y., Zhang R., Yu P., Ma Z., Kainov D. E., de Man R. A., Peppelenbosch M. P., Pan Q. Antivir. Res. 2020, 184, 104967. doi: 10.1016/j.antiviral.2020.104967.
  8. Cihák A. Oncology. 1974, 30, 405–422. doi 10.1159/ 000224981.
  9. Liliemark J. Clin. Pharmacokinet. 1997, 32, 120–131. doi: 10.2165/00003088–199732020–00003.
  10. Kantarjian H.M., O′Brien S., Cortes J., Giles F. J., Faderl S., Issa J. P., Garcia-Manero G., Rios M. B., Shan J., Andreeff M., Keating M., Talpaz M. Cancer. 2003, 98, 522–528. doi: 10.1002/cncr.11543.
  11. Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Lancet. 1994, 344, 1255–1260. doi: 10.1016/S0140–6736(94)90750–1.
  12. Tournilhac O., Cazin B., Leprètre S., Diviné M., Maloum K., Delmer A., Grosbois B., Feugier P., Maloisel F., Villard F., Villemagne B., Bastit D., Belhadj K., Azar N., Michallet M., Manhès G., Travade P. Blood. 2004, 103, 363–365. doi: 10.1182/blood-2003–05–1449.
  13. http://www.cancer.gov/cancertopics/druginfo/fda-nelarabine; Архивная копия от 11 сентября 2014 на Wayback Machine FDA Approval for Nelarabine.
  14. Wangsomboonsiri W., Mahasirimongkol S., Chantarangsu S., Kiertiburanakul S., Charoenyingwattana A., Komindr S., Thongnak C., Mushiroda T., Nakamura Y., Chantratita W., Sungkanuparph S. Clin. Infect. Dis 2010, 50, 597–604. doi: 10.1086/650003.
  15. Lai C.L., Leung N., Teo E. K., Tong M., Wong F., Hann H. W., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown N. A. Gastroenterology. 2005, 129, 528–536. doi: 10.1016/j.gastro.2005.05.053.
  16. Wilhelmus K.R. Cochrane Database Syst Rev. 2015, 1, CD002898. doi: 10.1002/14651858.CD002898.pub5
  17. Ko W.C., Rolain J. M., Lee N. Y., Chen P. L., Huang C. T., Lee P. I., Hsueh P. R. Int. J. Antimicrob. Agents. 2020, 55, 105933. doi: 10.1016/j.ijantimicag.2020.105933.
  18. Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Eur. J. Med. Chem. 2016, 108, 616–622. doi: 10.1016/j.ejmech.2015.12.029.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Russian Academy of Sciences, 2024